STAT3 and breast carcinoma: Our previous studies have shown that imipramine reduces the activity of AKT, extracellular signal‐regulated kinase (ERK), signal transducer and activator of transcription 3 (STAT3) and nuclear factor‐kappaB (NF‐κB), thereby interfering with the progression of lung, oral and breast cancers [20, 21].